Table 1.
Skin related changes of cancer chemotherapy
| Skin change | Patients only on chemotherapy (126) n (%) | Patients on combination therapy (100) n (%) | Total (226) n (%) |
|---|---|---|---|
| Skin hyperpigmentation | 55 (43.65) | 50 (50) | 105 (46.46) |
| Pruritus | 55 (43.65) | 46 (46) | 101 (44.69) |
| Palmar-plantar erythrodysesthesia (PPE) | 35 (27.78) | 27 (27) | 62 (28.76) |
| Xerosis | 18 (14.28) | 28 (28) | 46 (20.35) |
| Acneiform eruptions | 6 (4.76) | 11 (11) | 17 (7.52) |
| Flagellate dermatitis | 7 (5.55) | 8 (8) | 15 (6.64) |
| Photosensitivity | 6 (4.76) | 6 (6) | 12 (5.31) |
| Serpentine supravenous hyperpigmentation | 2 (1.59) | 8 (8) | 10 (4.42) |
| Intertrigo | 4 (3.17) | 5 (5) | 9 (3.98) |
| Inflammation of preexisting keratosis | 3 (2.38) | 5 (5) | 8 (3.54) |
| Papulopustular rash | 3 (2.38) | 5 (5) | 8 (3.54) |
| Maculopapular rash | 7 (5.55) | 0 | 7 (3.10) |
| Urticaria | 3 (2.38) | 3 (3) | 6 (2.65) |
| Skin induration | 3 (2.38) | 3 (3) | 6 (2.65) |
| Skin atrophy | 2 (1.59) | 3 (3) | 5 (2.21) |
| Skin infection | 1 (0.79) | 2 (2) | 3 (1.33) |
| Bullous dermatitis | 2 (1.59) | 1 (1) | 3 (1.33) |
| Erythema multiforme/SJS/TEN | 1 (0.79) | 1 (1) | 2 (0.88) |
| Skin ulceration | 0 | 2 (2) | 2 (0.88) |
| Wound complication | 0 | 2 (2) | 2 (0.88) |
| Autoimmune reactions | 1 (0.79) | 0 | 1 (0.44) |
| Fat atrophy | 1 (0.79) | 0 | 1 (0.44) |
| Skin hypopigmentation | 1 (0.79) | 0 | 1 (0.44) |
| Others | 3 (2.38) | 2 (2) | 5 (2.21) |
Note: SJS - Stevens Johnson syndrome, TEN - Toxic epidermal necrolysis